Zeria Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months and Full Year Ending March 31, 2022
May 11, 2021 at 12:30 pm IST
Share
Zeria Pharmaceutical Co., Ltd. provided earnings guidance for the six months and full year ending March 31, 2022. For the first six months, the company expected net sales of JPY 29,000 million, operating profit of JPY 2,100 million and profit of JPY 1,500 million or JPY 32.82 per share.
For the year, the company expected net sales of JPY 60,000 million, operating profit of JPY 4,800 million and profit of JPY 3,300 million or JPY 72.21 per share.
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
ZERIA PHARMACEUTICAL CO., LTD. 
